Public Assessment Report UK PAR Deferiprone 500mg Film-coated Tablets Deferiprone 1000mg Film-coated Tablets (Deferiprone) UK Licence No: PL 30306/0763-0764 Actavis Group PTC ehf
Public Assessment Report
UK PAR
Deferiprone 500mg Film-coated Tablets
Deferiprone 1000mg Film-coated Tablets
(Deferiprone)
UK Licence No: PL 30306/0763-0764
Actavis Group PTC ehf
Deferiprone 500mg and 1000mg Film-coated Tablets PL 30306/0763-0764
2
LAY SUMMARY
Deferiprone 500mg Film-coated Tablets
Deferiprone 1000mg Film-coated Tablets
(Deferiprone)
This is a summary of the Public Assessment Report (PAR) for Deferiprone 500mg Film-coated Tablets
(PL 30306/0763) and Deferiprone 1000mg Film-coated Tablets (PL 30306/0764). For ease of reading,
the products may be referred to as ‘Deferiprone Tablets’ or ‘Deferiprone 500 mg and 1000mg Tablets’
in this lay summary. The lay summary explains how the applications for Deferiprone 500mg and
1000mg Film-coated Tablets were assessed and their authorisations recommended, as well as the
conditions of use. It is not intended to provide practical advice on how to use Deferiprone 500mg and
1000mg Film-coated Tablets. For practical information about using Deferiprone 500mg and 1000mg
Film-coated Tablets, patients should read the package leaflet or contact their doctor or pharmacist.
What are Deferiprone Tablets and what are they used for?
Deferiprone 500mg and 1000mg Tablets are ‘generic’ medicines’. This means that Deferiprone 500mg
and 1000mg Tablets are similar to ‘reference medicines’ already authorised in the EU called are
Ferriprox 500 mg and 1000 mg film-coated tablets (Apotex Europe B.V., Netherlands), first licensed in
the EU on 25 August 1999..
Deferiprone Tablets are used to treat iron overload caused by frequent blood transfusions in patients
who have a condition called thalassaemia major when deferoxamine therapy is contraindicated or
inadequate.
How do Deferiprone Tablets work?
Deferiprone Tablets contain the active substance, deferiprone, which is a medicine that removes iron
from the body.
How are Deferiprone Tablets used?
Deferiprone Tablets are taken by mouth.
The patient should always take the tablets exactly as advised by his/her doctor or pharmacist. The
patient should check with his/her doctor or pharmacist if he/she is not sure.
Deferiprone Tablets can be taken with or without food; however, the patient may find it easier to
remember to take the medicine if the tablets are taken with meals.
The 500mg and 1000mg tablets can be divided in equal doses. If the tablets are divided, the divided dose
should be taken within 3 days.
Adults
The recommended dose is based on the patient’s body weight.
• The patient’s doctor will decide on the dose.
• The usual dose is 25mg/kg, three times per day (to give a total daily dose of 75 mg/kg).
• The total daily dose should not exceed 100 mg/kg.
• The patient should take the first dose in the morning, the second dose at midday and the third dose in
the evening.
Deferiprone 500mg and 1000mg Film-coated Tablets PL 30306/0763-0764
3
Please read section 3 of the package leaflet for detailed information on dosing recommendations, route
of administration and the duration of treatment.
Deferiprone Tablets can only be obtained with a prescription.
What benefits of Deferiprone Tablets have been shown in studies?
As Deferiprone 500mg and 1000mg Tablets are generic medicines, studies in patients have been limited
to tests to determine that they are bioequivalent to their respective reference medicines, Ferriprox 500
mg and 1000 mg film-coated tablets (Apotex Europe B.V., Netherlands). Two medicines are
bioequivalent when they produce the same levels of the active substance in the body.
What are possible side effects of Deferiprone Tablets?
Because Deferiprone 500mg and 1000mg Tablets are generic medicines that are considered
bioequivalent to the reference medicines, Ferriprox 500 mg and 1000 mg film-coated tablets (Apotex
Europe B.V., Netherlands), the benefits and possible side effects are taken as being the same as the
respective reference medicines.
For the full list of all side effects reported with Deferiprone Tablets, see section 4 of the package leaflet.
For the full list of restrictions, see the package leaflet.
Why are Deferiprone Tablets approved?
It was concluded that, in accordance with EU requirements, Deferiprone Tablets have been shown to
have comparable quality and to be bioequivalent to Ferriprox 500 mg and 1000 mg film-coated tablets
(Apotex Europe B.V., Netherlands). Therefore, the MHRA decided that, as for Ferriprox 500mg and
1000mg film-coated tablets (Apotex Europe B.V., Netherlands), the benefits outweigh the identified
risks and recommended that Deferiprone Tablets can be approved for use.
What measures are being taken to ensure the safe and effective use of Deferiprone Tablets?
A Risk Management Plan has been developed to ensure that Deferiprone Tablets are used as safely as
possible. Based on this plan, safety information has been included in the Summaries of Product
Characteristics and the package leaflet for Deferiprone Tablets, including the appropriate precautions to
be followed by healthcare professionals and patients.
Known side effects are continuously monitored. Furthermore, new safety signals reported by
patients/healthcare professionals will be monitored/reviewed continuously.
Other information about Deferiprone Tablets
Marketing Authorisations were granted for Deferiprone 500mg and 1000mg Tablets to Actavis Group
PTC ehf on 13 December 2017.
The full PAR for Deferiprone Tablets follows this summary.
For more information about treatment with Deferiprone Tablets read the package leaflet, or contact your
doctor or pharmacist.
This summary was last updated in February 2018.
Deferiprone 500mg and 1000mg Film-coated Tablets PL 30306/0763-0764
4
SCIENTIFIC DISCUSSION
TABLE OF CONTENTS
I Introduction Page 5
II Quality aspects Page 5
III Non-clinical aspects Page 8
IV Clinical aspects Page 8
V User consultation Page 10
VI Overall conclusion, benefit/risk assessment and recommendation Page 10
Steps taken after Authorisation – Summary Page 20
Deferiprone 500mg and 1000mg Film-coated Tablets PL 30306/0763-0764
5
Scientific discussion
I INTRODUCTION
The Medicines and Healthcare products Regulatory Agency (MHRA) granted Actavis Group PTC ehf
Marketing Authorisations for the medicinal products Deferiprone 500mg and 1000mg Film-coated
Tablets (PL 30306/0763-0764) on 13 December 2017. For ease of reading, the products may be referred
to as ‘Deferiprone Tablets’ or ‘Deferiprone 500 mg and 1000mg Tablets’ in this scientific discussion.
These are Prescription Only Medicines (POM) indicated for the treatment of iron overload in patients
with thalassaemia major when deferoxamine therapy is contraindicated or inadequate.
The applications for Deferiprone 500mg and 1000mg Tablets were submitted in accordance to Article
10(1) of Directive 2001/83/EC, as amended, as generic applications. The applications cross-refer to the
reference products Ferriprox 500 mg and 1000 mg film-coated tablets (Apotex Europe B.V.,
Netherlands), which were first authorised in the EU via the Centralised Procedure on 25 August 1999..
The active substance, deferiprone, binds to iron in a 3:1 molar ratio. Clinical studies have demonstrated
that deferiprone is effective in promoting iron excretion and that a dose of 25 mg/kg three times per day
can prevent the progression of iron accumulation as assessed by serum ferritin, in patients with
transfusion-dependent thalassaemia. However, chelation therapy may not necessarily protect against
iron-induced organ damage.
A bioequivalence study was submitted to support the applications comparing the applicant’s test product
Deferiprone 1000 mg film-coated tablets (Genepharm S.A., Greece) with the reference product
Ferriprox 1000mg film-coated tablets (Apotex Europe BV, Netherlands), under fasting conditions. The
applicant has stated that the bioequivalence study was conducted in accordance with Good Clinical
Practice (GCP).
With the exception of the bioequivalence study, no new non-clinical or clinical data were submitted,
which is acceptable given that the applications were based on being generic medicinal products of
originator products that have been in clinical use for over 10 years.
The MHRA has been assured that acceptable standards of Good Manufacturing Practice (GMP) are in
place at all sites responsible for the manufacture, assembly and batch release of these products.
No new or unexpected safety concerns arose during review of information provided by the Marketing
Authorisation Holder and it was, therefore, judged that the benefits of Deferiprone Tablets outweigh the
risks and Marketing Authorisations were granted.
II QUALITY ASPECTS
II.1 Introduction
The submitted documentation concerning the proposed products is of sufficient quality and meets the
current EU regulatory requirements.
The quality overall summary has been written by an appropriately qualified person and is a suitable
summary of the pharmaceutical aspects of the dossier.
The tablets are white to off-white, film-coated, with a score line on one side and plain on the other, with
dimensions of 14.2mm x 8.2mm (500mg strength tablet) or 19.2mm x 9.2mm (1000mg strength tablet).
The tablets can be divided into equal doses.
Each tablet contains 500mg or 1000mg of the active substance, deferiprone. The products also contain
pharmaceutical excipients in the tablet core and tablet coating, namely pregelatinised maize starch,
Deferiprone 500mg and 1000mg Film-coated Tablets PL 30306/0763-0764
6
magnesium stearate, hypromellose, hydroxypropylcellulose, titanium dioxide and macrogol. Appropriate
justification for the inclusion of each excipient has been provided.
The finished products are supplied in:
Polyvinylchloride/polyethylene/polvinylidene chloride - aluminium blisters, in a pack size of 50
(1000mg strength tablets only) and 100 (500mg strength tablets only) film-coated tablets.
Satisfactory specifications and Certificates of Analysis for the primary packaging materials have been
provided. All primary packaging complies with current European regulations concerning materials in
contact with foodstuff.
II.2 DRUG SUBSTANCE
Deferiprone
INN: Deferiprone
Chemical Name: 1,2-Dimethyl-3-hydroxypyridin-4 one;
1,2-Dimethyl-3-hydroxypyrid-4-one;
1,2-Dimethyl-3-hydroxypyridone-4;
1,2-Dimethyl-3-hydroxy-4-pyridone;
3-Hydroxy-1,2-dimethyl-4(1H)-pyridinone.
Molecular formula: C7H9NO2
Mr: 139.15
Structure:
Appearance: White crystalline powder, almost odourless
Solubility:
Polymorphism Deferiprone does not exhibit polymorphism
Deferiprone is not the subject of a European Pharmacopoeia monograph.
Synthesis of the active substance from the designated starting materials has been adequately described
and appropriate in-process controls and intermediate specifications are applied. Satisfactory
specification tests are in place for all starting materials and reagents and these are supported by relevant
Certificates of Analysis. Appropriate proof-of-structure data have been supplied. All potential known
impurities have been identified and characterised.
An appropriate specification is provided for the active substance. Analytical methods have been
appropriately validated and are satisfactory for ensuring compliance with the relevant specifications.
Batch analyses data are provided that comply with the proposed specification.
Satisfactory Certificates of Analysis have been provided for all working standards.
Suitable specifications have been provided for all packaging used. The primary packaging has been
shown to comply with current guidelines concerning contact with foodstuff.
Deferiprone 500mg and 1000mg Film-coated Tablets PL 30306/0763-0764
7
Appropriate stability data have been generated to support a suitable retest period when stored in the
proposed packaging.
II.3 MEDICINAL PRODUCT
Pharmaceutical Development
The objective of the development programme was to formulate safe, efficacious, stable film-coated
tablets, which were bioequivalent to Ferriprox 500 mg and 1000 mg film-coated tablets (Apotex Europe
B.V., Netherlands). Suitable pharmaceutical development data have been provided for these
applications.
Comparative in vitro dissolution profiles have been provided for these products and the respective
reference products. The dissolution profiles were satisfactory.
All excipients comply with their respective European Pharmacopoeia monographs. Satisfactory
Certificates of Analysis have been provided for all excipients.
None of the excipients contain materials of animal or human origin.
These products do contain or consist of genetically modified organisms (GMO).
Manufacturing Process
Satisfactory batch formulae have been provided for the manufacture of all strengths of the product,
along with an appropriate description of the manufacturing process. The manufacturing process has been
validated with pilot scale batches and has shown satisfactory results. The Marketing Authorisation
Holder has committed to performing process validation studies on future full-scale production batches.
Control of Finished Product
The finished product specifications are acceptable. Test methods have been described that have been
validated adequately. Batch data that comply with the release specifications have been provided.
Certificates of Analysis have been provided for all working standards used.
Stability of the Product
Finished product stability studies were performed in accordance with current guidelines, on batches of
finished product in the packaging proposed for marketing. Based on the results, a shelf life of 48 months
for the unopened product, with no special storage conditions, has been accepted. Half tablets can be
stored for 3 days at room temperature (below 25°C) in the original packaging.
Suitable post approval stability commitments have been provided to continue stability testing on batches
of finished product.
Bioequivalence/Bioavailability
Satisfactory Certificates of Analysis have been provided for the test and reference batches used in the
bioequivalence study.
II.4 Discussion on chemical, pharmaceutical and biological aspects
It is recommended that Marketing Authorisations are granted for these applications for Deferiprone
Tablets, from a quality of view.
Deferiprone 500mg and 1000mg Film-coated Tablets PL 30306/0763-0764
8
III NON-CLINICAL ASPECTS
III.1 Introduction
The pharmacodynamic, pharmacokinetic and toxicological properties of deferiprone are well known. No
new non-clinical data have been submitted for these applications and none are required.
The applicant has provided an overview based on published literature. The non-clinical overview has
been written by an appropriately qualified person and is satisfactory, providing an appropriate review of
the relevant non-clinical pharmacology, pharmacokinetics and toxicology.
III.2 Pharmacology
No new data have been submitted and none are required for applications of this type. Refer to Section
III.1, Introduction, above.
III.3 Pharmacokinetics
No new data have been submitted and none are required for applications of this type. Refer to Section
III.1, Introduction, above.
III.4 Toxicology
No new data have been submitted and none are required for applications of this type. Refer to Section
III.1, Introduction, above.
III.5 Ecotoxicity/Environmental Risk Assessment (ERA)
Suitable justification has been provided for non-submission of an Environmental Risk Assessment. As
these products are intended for generic substitution with products that are already marketed, no increase
in environmental exposure to deferiprone is anticipated. Thus, the justification for non-submission of an
Environmental Risk Assessment is accepted.
III.6 Discussion of the non-clinical aspects
It is recommended that Marketing Authorisations are granted for Deferiprone Tablets, from a
non-clinical point of view.
IV. CLINICAL ASPECTS
IV.1 Introduction
The clinical pharmacology of deferiprone is well-known.
In accordance with the regulatory requirements CPMP/EWP/QWP/1401/98 Rev. 1/Corr**, Guideline on
the Investigation of Bioequivalence, the Marketing Authorisation Holder submitted the results from a
bioequivalence study to support these generic applications.
With the exception of data from the bioequivalence study, no new pharmacodynamic or
pharmacokinetic data are provided or required for these applications.
IV.2 Pharmacokinetics
The clinical pharmacokinetic properties of deferiprone are well-known.
In support of the applications, a bioequivalence study was submitted. Details of the study are provided
below.
A randomised, open-label, two-treatment, two-period, two-sequence, single-dose, crossover
bioequivalence study comparing the pharmacokinetics of the applicant’s test product Deferiprone
1000 mg film-coated tablets (Genepharm S.A., Greece) and the reference product Ferriprox
1000mg film-coated tablets (Apotex Europe BV, Netherlands) in healthy adult human male
subjects under fasting conditions.
Deferiprone 500mg and 1000mg Film-coated Tablets PL 30306/0763-0764
9
The subjects were administered one tablet of either the test or the reference product with 240 ml of
water, after at least a 10-hour overnight fast. Blood samples were collected before and up to and
including 24 hours after each administration. The washout period between the treatment phases was
5 days. The statistical results for primary pharmacokinetic parameters of deferiprone are summarised
below:
Table 1: Geometric Means, Ratio of Means, and 90% Confidence Intervals for deferiprone
Cmax maximum plasma concentration
AUC0-t area under the plasma concentration-time curve from time zero to t hours
AUC0-inf area under the plasma concentration-time curve from time zero to infinity
CV% Coefficient of variation
Ratios and 90% CI calculated from ln-transformed data
The 90% confidence intervals of the test/reference ratio for Cmax and AUC values lie within the
acceptable limits of 80.00% to 125.00%, in line with the Guideline on the Investigation of
Bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1/Corr**). Thus, the data support the claim that the
applicant’s test product, Deferiprone 1000 mg film-coated tablets (Genepharm S.A., Greece), is
bioequivalent to the reference product, Ferriprox 1000mg film-coated tablets (Apotex Europe BV,
Netherlands), under fasting conditions.
As the 500mg and 1000mg strength tablets of the test product meet the criteria for a biowaiver specified
in the Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1/Corr**), the
results and conclusions from the bioequivalence study with the 1000mg strength tablet can be
extrapolated to the 500mg strength tablet.
IV.3 Pharmacodynamics
The clinical pharmacodynamic properties of deferiprone are well-known. No new pharmacodynamics
data were submitted and none are required for applications of this type.
IV.4 Clinical Efficacy
The clinical efficacy of deferiprone is well-known. No new efficacy data were presented for applications
of this type.
IV.5 Clinical Safety
With the exception of the safety data generated during the bioequivalence study no new safety data were
submitted and none are required for applications of this type. The safety profile of deferiprone is
well-known. No new or unexpected safety issues were raised during the bioequivalence study.
IV.6 Risk Management Plan
The MAH has submitted a Risk Management Plan, in accordance with the requirements of Directive
2001/83/EC as amended, describing the pharmacovigilance activities and interventions designed to
identify, characterise, prevent or minimise risks relating to Deferiprone Tablets.
Deferiprone 500mg and 1000mg Film-coated Tablets PL 30306/0763-0764
10
A summary of safety concerns is listed in the table below:
Routine pharmacovigilance activities are acceptable to monitor all the safety concerns described in the
Risk Management Plan.
Routine risk minimisation activities are acceptable to monitor the safety concerns with the exception of
‘neutropenia’, ‘agranulocytosis’ and ‘use in pregnancy’.
Additional risk minimisation activities for the safety concerns ‘neutropenia’, ‘agranulocytosis’ and ‘use
in pregnancy’ include provision of the following:
• wallet-sized, tear-away, patient/carer reminder cards within the product pack to increase patient
awareness about the importance of regular monitoring of the neutrophil count during treatment with
deferiprone and to increase awareness of the significance of any symptoms of infection while taking
deferiprone.
•
IV.7 Discussion of the clinical aspects
It is recommended that Marketing Authorisations are granted for Deferiprone Tablets.
V. USER CONSULTATION
A package leaflet has been evaluated via a user consultation study in accordance with the requirements
of Articles 59(3) and 61(1) of Directive 2001/83/EC, as amended. The language used for the purpose of
user testing the pack leaflet was English.
The results show that the package leaflet meets the criteria for readability as set out in the guideline on
the readability of the label and package leaflet of medicinal products for human use.
VI. OVERALL CONCLUSION, BENEFIT/RISK ASSESSMENT AND
RECOMMENDATION
The quality of the products is acceptable, and no new non-clinical or clinical safety concerns have been
identified. Extensive clinical experience with deferiprone is considered to have demonstrated the
therapeutic value of the compound. Bioequivalence between the test and reference products has been
demonstrated in accordance with the current CHMP guidelines.
The benefit/risk assessment is therefore considered to be positive.
The grant of Marketing Authorisations is recommended.
Deferiprone 500mg and 1000mg Film-coated Tablets PL 30306/0763-0764
11
The SmPCs, PIL and labelling text are satisfactory and in line with current guidance.
In accordance with Directive 2010/84/EU, the current version of the SmPCs and PIL is available on the
MHRA website. The current labelling is presented below.
The Marketing Authorisation Holder has submitted the text version only and has committed to
submitting mock-up livery to the regulatory authorities for approval before packs are marketed.
Deferiprone 500mg and 1000mg Film-coated Tablets PL 30306/0763-0764
12
Deferiprone 500mg Film-coated Tablets:
Deferiprone 500mg and 1000mg Film-coated Tablets PL 30306/0763-0764
13
Deferiprone 500mg and 1000mg Film-coated Tablets PL 30306/0763-0764
14
Deferiprone 500mg and 1000mg Film-coated Tablets PL 30306/0763-0764
15
Deferiprone 500mg and 1000mg Film-coated Tablets PL 30306/0763-0764
16
Deferiprone 1000mg Film-coated Tablets:
Deferiprone 500mg and 1000mg Film-coated Tablets PL 30306/0763-0764
17
Deferiprone 500mg and 1000mg Film-coated Tablets PL 30306/0763-0764
18
Deferiprone 500mg and 1000mg Film-coated Tablets PL 30306/0763-0764
19
Deferiprone 500mg and 1000mg Film-coated Tablets PL 30306/0763-0764
20
Deferiprone 500mg Film-coated Tablets
Deferiprone 1000mg Film-coated Tablets
(Deferiprone)
PL 30306/0763-0764
STEPS TAKEN AFTER AUTHORISATION-SUMMARY
Date submitted Application
type
Scope Outcome